Aprea Therapeutics
APRE
18 hedge funds and large institutions have $3.77M invested in Aprea Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 12 closing their positions.
623% more capital invested
Capital invested by funds: $521K → $3.77M (+$3.25M)
22.59% more ownership
Funds ownership: 0.15% → 22.74% (+23%)
25% less funds holding
Funds holding: 24 → 18 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.55M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.07M |
| 3 |
Walleye Capital
New York
|
+$689K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$627K |
| 5 |
Morgan Stanley
New York
|
+$5.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$59K |
| 2 |
Millennium Management
New York
|
-$53K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$48K |
| 4 |
Jane Street
New York
|
-$16.9K |
| 5 |
State Street
Boston,
Massachusetts
|
-$13.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$4.93K | -668 | Closed |
|
27
Stifel Financial
St. Louis,
Missouri
| – | -$3.31K | -500 | Closed |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$746 | -113 | Closed |
|
29
Citadel Advisors
Miami,
Florida
| – | -$411 | -64 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$170 | +23 | New |
|
APRE Hedge Fund Activity: Q1 2023 in Review
18 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2023, worth a combined $3.77M — up 623% from $521K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of APRE and 6 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $2.55M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $59K sold.
- 18 institutional investors held Aprea Therapeutics (APRE) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $3.77M of Aprea Therapeutics stock for Q1 2023, up 623% quarter-over-quarter.
- 6 funds opened new Aprea Therapeutics positions in Q1 2023 and 12 closed out, a net change of -6 holders.
- The largest Aprea Therapeutics buyer in Q1 2023 was AIGH Capital Management, an estimated $2.55M added.
- The largest Aprea Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $59K sold.
Based on aggregated 13F filings for Q1 2023.